Calbostar400 mg

Calbostar is a mineral supplement used to provide supplemental calcium in the following settings:

Established / commonly used indications

• Prevention and treatment of dietary calcium deficiency, when dietary intake alone is insufficient.
• As an adjunct to diet and, where prescribed, vitamin D and other agents, in the prevention and management of osteoporosis and low bone mineral density, particularly in postmenopausal women and the elderly.
• Supportive calcium supplementation during periods of increased calcium requirement, such as pregnancy and lactation, growth in children and adolescents, and in the elderly.
• Adjunctive management of hypocalcaemia (under medical supervision), usually alongside vitamin D and correction of the underlying cause.

Marketing claim (evidence-limited)

Calbostar is sometimes promoted as having superior absorption/bioavailability compared with other calcium salts (e.g., calcium carbonate or calcium citrate). This claim is not well substantiated by robust clinical evidence; Calbostar should be regarded as a calcium-delivery form with efficacy comparable to other calcium salts, used for the same core purpose of calcium supplementation.

Each unit (tablet/capsule) contains Calcium Orotate equivalent to a labelled amount of elemental calcium. The exact elemental calcium content varies by brand and strength; always check the product label/pack insert for the precise elemental calcium yield, as this determines the actual calcium dose delivered.

Calbostar is the orotate salt of calcium, combining calcium with orotic acid. It is marketed as an oral mineral supplement intended to supply elemental calcium for skeletal health and general calcium homeostasis. Like other calcium salts (carbonate, citrate, gluconate, lactate), Calbostar functions primarily as a source of elemental calcium once absorbed; the orotate moiety itself has no established independent pharmacological indication in this context.

Calbostar belongs to the therapeutic class of calcium supplements / minerals and electrolytes, used for prevention and treatment of calcium deficiency and as an adjunct in bone health.

Calcium Orotate dissociates in the gastrointestinal tract to release calcium ions and orotate. Calcium is absorbed mainly in the duodenum and proximal jejunum by both active, vitamin D-dependent transport and passive paracellular diffusion; absorption efficiency depends on vitamin D status, gastric acidity, dietary factors, and the amount of elemental calcium ingested at one time.

Absorbed calcium is essential for bone mineralisation, neuromuscular transmission, cardiac contractility, blood coagulation, and enzyme activity. Excess calcium is excreted mainly via the kidneys, with renal tubular reabsorption regulated by parathyroid hormone and vitamin D.

Orotic acid is a naturally occurring intermediate of pyrimidine metabolism; at the doses present in Calcium Orotate supplements it is not considered to contribute a distinct pharmacological effect beyond acting as a carrier salt for calcium.

Calbostar tablets/capsules are usually swallowed whole with a glass of water, preferably with or after meals. Divide the total daily dose into two or more smaller doses if the elemental calcium amount per dose is high, to improve absorption and reduce gastrointestinal discomfort.

Calcium supplied by Calbostar can reduce the absorption of several other minerals and medicines when taken at the same time:

• Tetracyclines and fluoroquinolone antibiotics (e.g., doxycycline, ciprofloxacin): calcium forms non-absorbable chelates, reducing antibiotic absorption and efficacy. Separate administration by at least 2–3 hours.
• Bisphosphonates (e.g., alendronate): calcium markedly reduces bisphosphonate absorption; bisphosphonates should be taken well before Calbostar, per product labelling.
• Levothyroxine: calcium can reduce absorption; separate dosing by at least 4 hours.
• Iron and zinc supplements: calcium can competitively reduce the absorption of iron and zinc; separate dosing where possible.
• Thiazide diuretics: concurrent use can increase risk of hypercalcaemia due to reduced renal calcium excretion.
• Digoxin: hypercalcaemia can increase the risk of digoxin toxicity and cardiac arrhythmia; caution with concurrent use.

Side effects with Calbostar are generally mild and dose-related:

• Gastrointestinal: constipation, bloating, flatulence, mild abdominal discomfort, nausea.
• With excessive intake: symptoms of hypercalcaemia — fatigue, headache, dry mouth, increased thirst, polyuria, anorexia, nausea/vomiting (see Overdose).
• Rare: hypersensitivity reactions (rash, itching).

Calcium is an essential dietary mineral in pregnancy and lactation, and appropriate supplementation is often recommended by physicians when dietary intake is inadequate. However, Calbostar should be used in pregnancy and lactation only if clearly needed and the potential benefit justifies any potential risk, and only under medical advice regarding dose, since excessive total calcium intake (diet plus supplement) is not advisable in either pregnancy or lactation. Consult a physician before use in these situations.

Use Calbostar with caution in:

• Renal impairment: calcium handling and excretion are altered; accumulation and hypercalcaemia risk are increased. Use only under medical supervision, with monitoring of renal function and serum calcium.
• History of calcium-containing kidney stones: supplementation may increase recurrence risk; use only if advised by a physician, with adequate fluid intake.
• Avoid exceeding the recommended total daily calcium intake from all sources combined (diet plus supplement), as chronic excess intake raises the risk of hypercalcaemia, vascular/soft-tissue calcification, and kidney stones.
• Patients on interacting medicines (see Interactions) should separate dosing as advised.
• Periodic monitoring of serum calcium is advisable with prolonged use, especially in at-risk patients.

Overdose or chronic excessive intake of Calbostar can cause hypercalcaemia, with symptoms such as nausea, vomiting, constipation, abdominal pain, muscle weakness, confusion, excessive thirst, polyuria, and in severe cases cardiac arrhythmia or renal impairment. If overdose is suspected, seek immediate medical attention or contact a poison control centre/emergency services promptly; do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: commonly used for age-related calcium deficiency and osteoporosis prevention; renal function should be considered when dosing.

Renal impairment: use with caution and medical supervision; see Precautions and Warnings.

Hepatic impairment: no well-established dose adjustment required; general caution advised.

Pediatric patients: use under medical guidance with weight/age-appropriate dosing; see Pediatric Uses.

Duration of Calbostar therapy depends on the indication and is determined by the prescribing physician — ranging from short-term correction of dietary deficiency to long-term maintenance therapy in chronic conditions such as osteoporosis. Periodic reassessment of calcium status is advisable during prolonged use.

Calcium Orotate belongs to the class of calcium salts / mineral and electrolyte supplements.

Calcium Orotate acts by supplying elemental calcium, which is absorbed from the gastrointestinal tract to correct or prevent calcium deficiency, support bone mineralisation, and maintain normal neuromuscular, cardiac, and enzymatic function. The orotate salt form serves as a carrier for calcium delivery without a separate, distinct pharmacological mechanism of its own.

Calbostar may be used in children and adolescents to prevent or treat dietary calcium deficiency and to support normal bone growth, under medical supervision, with dosing individualised according to age, weight, and recommended dietary calcium allowances. Safety and efficacy of specific commercial Calbostar products have not been separately established in infants, and use in this age group should only be under a physician's direction.